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btaining susceptibility, empirical treatment was adminis-
ered; a frequent reported combination therapy is tigecycline
lus colistin, but the empirical use of colistin could contribute
o selection of resistant strains.6 We avoided nephrotoxic
gents, and took into consideration the drug concentration
t the site of infection and potential adverse events. Car-
apenem monotherapy has a higher rate of treatment failure
ompared to combination therapy; moreover, only the com-
ination of meropenem, colistin, and tigecycline is associated
ith improved survival in patientswith blood infections.6 Col-
stinewas successfulwhen the isolate showed resistance to all
ested antibiotics. The use of a triple-drug regimen including
igecycline, colistin, and meropenem was linked to a reduced
isk of death.7
Toprevent the spreadof bacteria,measures suchasperirec-
al surveillance swabs, susceptibility tests, use of gowns and
loves, and strict hand hygiene were followed. Also, recipients
f kidneys from living donors were transferred from the oper-
ting room to a non-intensive setting, or underwent a reduced
tay in the ICU. Despite its limitations, this report shows that
TIs caused by KPC-Kp pose a threat to kidney transplant
atients.
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Table 1 – Baseline data and ﬁve-year evolution data
for patients diagnosed with HRD.
Baseline 5 Years A
Creatinine, mg/dL 1.03±0.05 1.14±0.1 0.051
Uric acid (mg/ml) 4.92±0.9 5.45±1.3 N/A
Potassium mmol/L 4.24±0.4 4.55±0.48 0.021
Calcium mg/dl 9.37±0.42 9.45±0.44 N/A
Haematocrits (%) 40.44±3 40.88±4 N/A
Urine protein (g) 0 0 N/A
MDRD (ml/min/1.73m2) 54.50±3 48.71±7 0.063
in normal range SCR, all of them female with an average age
of 76.5.1 A newly published Nephrology trial was performed
on a total of 183 subjects (64.5% female) with an average
age of 59.1±18.2 years. 21.4% or 25% of them would have
HRD if MDRD-4 or Cockroft-Gault equations respectively were
applied.2
Notwithstanding, only a few trials have focused on know-
ing what was the outcome of those patients diagnosed of HRD
over the course of time. In this study, both the clinical and
analytical evolutions of patients with HRD were assessed over
a period of ﬁve years.
According to “Ancianos con Enfermedad Renal Crónica del
Hospital General de Segovia” (Elderly people with Chronic
RenalDisease at the SegoviaGeneralHospital),which included
80 elderly people recruited between January and April 2006,
normal SCR range (≤1.1mg/dl) was found in 38 patients.3 Of
those, baseline characteristics and ﬁve-year follow up were
analyzed in patients diagnosed with HRD.
Out of the 80 patients, 18 (22.5%) could be considered as
carriers of HRD; all were female and their average age was
81.33±6 years. 33.3% were diabetic and 83.3% were diag-
nosed of hypertension. For baseline treatments, 66.7% were
on diuretics and 38.9% were on ACE inhibitors. During the
ﬁve-year clinical evolution, 1 of them (5.6%) presented de
novo ischaemic cardiopathy and 3 (16.7%) had cardiac failure
episodes; 8 (44.4%) patients died during that period. No patient
evolved to end-stage nephropathy or needed renal replace-
ment therapy. Baseline and post-ﬁve-year analytical data are
showed in the table below (Table 1).
Discussion
Our study found that around one-quarter of the analysed pop-
ulation could be considered asHRDcarriers, all ofwere female.
Our ﬁndings are similar to those of Pérez-Durillo et al. which
about 1.1ml/min/yr while patients still kept their SCR levels
within normal range without typical manifestations of renal
failure.
Conclusion: the term HRD should be avoided in elderly peo-
ple. In those female patientswhose SCR range remains normal
over time, the drop of UF might correspond to “physiological”
renal ageing and not to a “pathological” process.
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where HRD was registered in female patients. Another con-
tribution of our study was the evolution over time of these
patients; there was a slow decrease of GFR values, without
typical manifestations of renal failure (such as anaemia or
hypocalcaemia) or progression of renal failure to end-stage
nephropathy. Therefore, the term “hidden” in elderly female
patients with HRD might refer to the “physiological” GFR
drop associated with age. Our study conﬁrmed a drop of(http://creativecommons.org/licenses/by-nc-nd/4.0/).
